Skip to main content
. 2023 Mar 24;13(5):463–482. doi: 10.1016/j.jpha.2023.03.006

Fig. 13.

Fig. 13

Phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT) activator recilisib weaken the effect of ginsenoside Rk3 in inhibiting hepatocellular carcinoma (HCC) growth. (A) Cell viability of HepG2 and HCC-LM3 treated with or without 100 μM Rk3 and 10 μM recilisib. (B) Westerrn blotting detection of PI3K/AKT pathway, G1 phase, autophagy, and apoptosis related proteins of HepG2 and HCC-LM3 cells treated with 100 μM Rk3 and 10 μM recilisib. Data are shown as mean ± standard deviation (SD). ∗P < 0.05 compared with the control group, ∗∗P < 0.01 compared with the control group, ∗∗∗P < 0.001 compared with the control group, #P < 0.05 compared with the ginsenoside Rk3 group, ##P < 0.01 compared with the ginsenoside Rk3 group, ###P < 0.001 compared with the ginsenoside Rk3 group.